Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-21
2005-06-21
Solola, Taofiq (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S276400
Reexamination Certificate
active
06908935
ABSTRACT:
The compounds of the invention are represented by the following general structureor a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
REFERENCES:
patent: 5981599 (1999-11-01), Moe et al.
patent: 6011068 (2000-01-01), Nemeth et al.
patent: 6031003 (2000-02-01), Nemeth et al.
patent: 6103737 (2000-08-01), Cocuzza et al.
patent: 6172091 (2001-01-01), Cohen et al.
patent: 6225316 (2001-05-01), Bos et al.
patent: 6335338 (2002-01-01), Bhatnagar et al.
patent: 6403832 (2002-06-01), Oikawa et al.
patent: 6407111 (2002-06-01), Bos et al.
patent: 6436152 (2002-08-01), Chassot et al.
patent: 2002/0143212 (2002-10-01), Oikawa et al.
patent: 039051 (1981-04-01), None
patent: 0 933 354 (1999-08-01), None
patent: WO 93/04373 (1993-03-01), None
patent: WO 94/18959 (1994-09-01), None
patent: WO 95/11221 (1995-04-01), None
patent: WO 96/05818 (1996-02-01), None
patent: WO 96/09818 (1996-04-01), None
patent: WO 96/12697 (1996-05-01), None
patent: WO 96/31475 (1996-10-01), None
patent: WO 97/05252 (1997-02-01), None
patent: WO 97/37967 (1997-10-01), None
patent: WO 98/01417 (1998-01-01), None
patent: WO 98/37061 (1998-08-01), None
patent: WO 98/45255 (1998-10-01), None
patent: WO 99/01439 (1999-01-01), None
patent: WO 99/48888 (1999-09-01), None
patent: WO 00/21910 (2000-04-01), None
patent: WO 01/34562 (2001-05-01), None
patent: WO 01/90069 (2001-11-01), None
patent: WO 01/96307 (2001-12-01), None
patent: WO 01/96312 (2001-12-01), None
patent: WO 01/96365 (2001-12-01), None
patent: WO 03/020723 (2003-03-01), None
U.S. Appl. No. 10/444,945, filed May 22, 2003, Kelly et al.
Nemeth et al. (1998), “Calcimimetics with potent and selective activity on the parathyroid calcium receptor,”Proc. Natl. Acad. Sci. USA95:4040-4045.
Berge et al., “Pharmaceutical Salts,”J. Pharm. Sci.66(1):1-19 (1977).
Brown et al., “Neomycin Mimics the Effects of High Extracellular Calcium Concentrations on Parathyroid Function in Dispersed Bovine Parathyroid Cells,”Endocrinology128(6):3047-3054 (1991).
Bungaard et al., “A Novel Solution-Stable, Water-Soluble Prodrug Type for Drugs Containing a Hydroxyl or an NH-Acidic Group,”J. Med. Chem.32(12):25032507 (1989).
Chen et al., “The Diltiazem Analog TA-3090 Mimics the Actions of High Extracellular Ca2+on Parathyroid Function in Dispersed Bovine Parathyroid Cells,”J. Bone Miner. Res.5(6):581-587 (1990).
Dauban et al., “N1-Arylsulfonyl-N2-(1-aryl)ethyl-3-phenylpropane-1,2-diamines as Novel Calcimimetics Acting on the Calcium Sensing Receptor,”Bioorg. Med. Chem. Let.10(17):2001-2004 (2000).
Garrett et al., “Calcitonin-Secreting Cells of the Thyroid Express an Extracellular Calcium Receptor Gene,”Endocrinology136(11):5202-5211, 1995.
J. Bone Miner. Res.9(Supple. 1):S282 (1994).
J. Bone Miner. Res.9(Supple. 1):S409 (1994).
Kabalka et al., “The Reduction of Azides With Borohydride Supported on an Ion Exchange Resin,”Synthetic Commun.20(2):293-299 (1990).
Keseru et al., “Total Synthesis of Plagiochins C, and D, Macrocyclic Bis(bibenzyl) Constituents ofPlagiochila Acantophylla,” Tetrahedron48(5):913-922 (1992).
Liedholm “Simple Synthetic Route to 4-Aminobenzaldehydes From anilines,”J. Chem. Soc., Perkin Trans.1:2234-2237 (1992).
Nemeth, “Regulation of Cytosolic Calcium by Extracellular Divalent Cations in C-cells and Parathyroid Cells,”Cell Calcium11:323-327 (1990).
Sande et al., “Borohydride Reducing Agent Derived From Anion Exchange Resin: Selective Reduction of α, β-unsaturated Carbonyl Compounds,”Tetrahedron Lett.25(32):3501-3504 (1984).
Svensson and Tunek, “The Design and Bioactivation of Presystemically Stable Prodrugs,”Drug Metabolism Reviews19(2):165-194 (1988).
Zaidi, “Intracellular Calcium in the Control of Osteoclast Function,”Biochem. Biophys. Res. Commun.167(2):807-812 (1990).
Zaidi, “Calcium Receptors' on Eukaryotic Cells with Special Reference to the Osteoclast,”Bioscience Reports10(6):493-507 (1990).
Coulter Thomas
Ghiron Chiara
Kelly Michael G.
Kincaid John F.
Miller Philip
Amgen Inc.
Howard Mary Susan
Levy Ron K.
Solola Taofiq
Watt Stuart L.
LandOfFree
Calcium receptor modulating agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Calcium receptor modulating agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calcium receptor modulating agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3519244